Trial to Determine Recommended Dose for Phase II Study
FLEMINGTON, NJ, USA I September 9, 2013 I Arno Therapeutics, Inc. (ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced it has submitted an Investigational Medicinal Product Dossier (IMPD) to the French Health Authority, L’Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM), to request the clinical trial authorization of a Phase I dose escalation study evaluating Arno’s lead compound onapristone in progesterone receptor positive tumors in post-menopausal women. Arno expects to initiate the Phase I trial in the fourth quarter of this year.
The submission follows the initiation of a pharmacokinetic (PK) study of onapristone in France last month. The PK study will determine the metabolism of the drug and the effect of food on drug absorption in healthy volunteers.
Onapristone is an anti-progestin hormone blocker that has been shown to have considerable anti-tumor activity in breast cancer. Onapristone appears to have a unique ability to block the activated progesterone receptor (APR), which is believed to be the mechanism that may inhibit the growth of breast, endometrial and other tumors. The APR has the potential to function as a biomarker of anti-progestin activity.
The goal of the Phase I study will be to define the recommended Phase II dose and determine the overall safety profile.
“On the heels of initiating the PK study of onapristone, the filing of an IMPD for a Phase I trial represents a second critical step in our lead compound’s clinical development program,” said Alexander Zukiwski, MD, Chief Medical Officer of Arno Therapeutics. “We believe the submitted package for onapristone meets the requirements necessary to begin Phase I trials in France later this year. Initiating the next phase in the development of this compound, along with developing a diagnostic test for a biomarker, is an important milestone for the Company as we continue to focus on bringing a targeted and personalized treatment to patients with an unmet medical need.”
Arno has selected Biotrial, a drug evaluation and pharmacology research company that is currently conducting the PK study, as its contract research organization for the Phase I trial.
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors. For more information about the company, please visit www.arnothera.com.
SOURCE: Arno Therapeutics
Post Views: 357
Trial to Determine Recommended Dose for Phase II Study
FLEMINGTON, NJ, USA I September 9, 2013 I Arno Therapeutics, Inc. (ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced it has submitted an Investigational Medicinal Product Dossier (IMPD) to the French Health Authority, L’Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM), to request the clinical trial authorization of a Phase I dose escalation study evaluating Arno’s lead compound onapristone in progesterone receptor positive tumors in post-menopausal women. Arno expects to initiate the Phase I trial in the fourth quarter of this year.
The submission follows the initiation of a pharmacokinetic (PK) study of onapristone in France last month. The PK study will determine the metabolism of the drug and the effect of food on drug absorption in healthy volunteers.
Onapristone is an anti-progestin hormone blocker that has been shown to have considerable anti-tumor activity in breast cancer. Onapristone appears to have a unique ability to block the activated progesterone receptor (APR), which is believed to be the mechanism that may inhibit the growth of breast, endometrial and other tumors. The APR has the potential to function as a biomarker of anti-progestin activity.
The goal of the Phase I study will be to define the recommended Phase II dose and determine the overall safety profile.
“On the heels of initiating the PK study of onapristone, the filing of an IMPD for a Phase I trial represents a second critical step in our lead compound’s clinical development program,” said Alexander Zukiwski, MD, Chief Medical Officer of Arno Therapeutics. “We believe the submitted package for onapristone meets the requirements necessary to begin Phase I trials in France later this year. Initiating the next phase in the development of this compound, along with developing a diagnostic test for a biomarker, is an important milestone for the Company as we continue to focus on bringing a targeted and personalized treatment to patients with an unmet medical need.”
Arno has selected Biotrial, a drug evaluation and pharmacology research company that is currently conducting the PK study, as its contract research organization for the Phase I trial.
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors. For more information about the company, please visit www.arnothera.com.
SOURCE: Arno Therapeutics
Post Views: 357
